Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Partnering Opens 600x60px
Document › Details

Danaher Corporation. (11/12/14). "Press Release: Danaher To Announce Future Change To Earnings Guidance At Baird Industrial Conference". Washington, D.C..

Organisation Organisation Danaher Corporation (NYSE: DHR)
  Group Danaher (Group)
Products Product laboratory equipment and instruments
  Product 2 analytical instrument
Persons Person Joyce, Thomas P., Jr. (Danaher 201503– promoted CEO before 25 years at Danaher)
  Person 2 Gugino, Matthew E. (Danaher 201407 VP Investor Relations)
     


Danaher Corporation (NYSE:DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will present at the Baird Industrial Conference in Chicago, Illinois today, Wednesday, November 12 at 8:30 a.m. CT. The audio will be simultaneously webcast and the presentation will be archived on the Investors section of www.danaher.com under Investor Events.

The Company also announced that beginning in 2015 it will begin to report and provide guidance for adjusted diluted net earnings per share ("Adjusted EPS") on a basis that adds back non-cash amortization charges. The Company will also continue its practice of excluding from Adjusted EPS special non-operating items, including those related to large acquisitions.

"We believe reporting Adjusted EPS, excluding non-cash intangibles amortization, is more reflective of Danaher's core operating results," said President and Chief Executive Officer, Thomas P. Joyce, Jr. "It will offer our shareholders greater consistency and transparency with regard to our true earnings power, providing them with a better understanding of how we are performing."

Non-cash intangibles amortization is expected to be approximately $450 million for the full year 2015, including acquisitions pending but not yet closed. Danaher will provide additional details and guidance for the full year 2015 using this methodology at its Investor and Analyst Meeting to be held in New York, New York on Thursday, December 11, 2014. There is no change to Danaher's previously communicated diluted net earnings per share guidance for the fourth quarter 2014.


ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands have unparalleled leadership positions in some of the most demanding and attractive markets, including health care, environmental and industrial. The company's globally diverse team of 66,000 associates is united by a common culture and operating system, the Danaher Business System. In 2013, Danaher generated $19.1 billion in revenue and its market capitalization exceeded $50 billion. For more information please visit www.danaher.com.


FORWARD LOOKING STATEMENTS

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated changes in its earnings guidance and reporting practices and the anticipated impact thereof, anticipated non-cash intangibles amortization for 2015 and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, contingent liabilities relating to acquisitions and divestures, our compliance with applicable laws and regulations (including regulations relating to medical devices and the healthcare industry) and changes in applicable laws and regulations, our ability to effectively address cost reductions and other changes in the healthcare industry, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, labor matters, international economic, political, legal, compliance and business factors, disruptions relating to man-made and natural disasters, security breaches or other disruptions of our information technology systems and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2013 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2014. These forward-looking statements speak only as of the date of this release and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.


Matthew E. Gugino, Vice President, Investor Relations, Danaher Corporation,Telephone: (202) 828-0850, Fax: (202) 828-0860

   
Record changed: 2015-01-26

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Danaher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Partnering Opens 560x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Partnering Opens 560x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px